二、对公司的影响 间质性肺疾病（interstitial lung disease，ILD）是一类主要累及肺间质和肺泡 腔、导致肺泡-毛细血管功能单位丧失的弥漫性肺疾病，其发病机制尚不明确，早期无 特异性临床表现。继发于结缔组织病（connective tissue disease，CTD）的结缔组织 病相关间质性肺病（connective tissue disease-interstitial lung disease，CTDILD） 是 ILD 的常见类型。有研究表明早期发现 ILD 并及时进行干预有助于改善 CTD 患者的预 后。涎液化糖链抗原-6（Krebs von den Lungen-6，KL-6）是在Ⅱ型肺细胞和支气管上 皮细胞上表达的大分子量糖蛋白，最先由日本学者 Kohno 等发现。当Ⅱ型肺泡上皮细胞 受损再生时，KL-6 的表达增加，且肺部基底膜的损坏导致血管通透性增加，KL-6 大量 证券代码：688575 证券简称：亚辉龙 公告编号：2025-073 深圳市亚辉龙生物科技股份有限公司 关于自愿披露取得医疗器械注册证的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 ...

证券代码：688575 证券简称：亚辉龙 深圳市亚辉龙生物科技股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 12 月 26 日 2025 年第二次临时股东大会会议资料 股东大会会议须知 2025 年第二次临时股东大会会议资料 为保障深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）全体股东 的合法权益，维护股东大会的正常秩序，保证股东大会的议事效率，确保本次股 东大会如期、顺利召开，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《深圳市亚辉龙生物科技股份有限公司章程》、《深圳市亚辉龙生物科技股份有 限公司股东大会议事规则》及中国证券监督管理委员会、上海证券交易所的有关 规定，特制定本须知。 一. 为确认出席大会的股东（或股东代表）或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二. 为保证本次股东大会的严肃性和正常秩序，切实维护与会股东（或股东代表） 的合法权益，除出席会议的股东（或股东代表）、公司董事、监事、高级管 理人员、见证律师及董事会邀请的人员外，公司有权依法拒绝其他人员进入 会场。 三. 请出席会议的股东（或股 ...

Market Strategy - The market is experiencing continuous volume contraction, with the retail sector showing resilience [5][10] - The overall A-share market saw a decline of 1.45%, with the Shanghai Composite Index down 1.11% and the ChiNext Index down 2.10% [9][10] - The retail sector is expected to benefit from government policies aimed at boosting consumption, especially as the year-end shopping season approaches [10][11] Company Tracking - Chongqing Beer (600132.SH) is involved in a lawsuit and is planning to sign a mediation agreement, which may impact its financials positively [38][41] - Miao Ke Lan Duo (600882.SH) announced expected related party transactions for 2026, with a projected decrease in procurement amounts compared to 2025 [33][35] - YH Bio (688575.SH) received two medical device registration certificates, indicating potential growth in its product offerings [36] - Mingyang Smart Energy (601615.SH) won a bid for a significant offshore wind power project valued at 1.834 billion yuan, enhancing its market position in renewable energy [42][44] Industry Dynamics - The Three Gorges Jiangsu Dafeng 800 MW offshore wind power project has achieved full capacity grid connection, marking a significant advancement in China's offshore wind energy capabilities [31][32] - The National Development and Reform Commission emphasized the need to enhance domestic consumption and support various sectors, including e-commerce and health care, to stimulate economic growth [21][22]

Policy Developments - The National Medical Insurance Administration has issued a three-year action plan to enhance the efficiency of medical insurance fund settlement, aiming to complete annual settlements by March 31 each year starting in 2028, with settlement funds accounting for about 3% of the annual medical insurance fund allocation [2] Medical Device Approvals - Jiukang Bio has received a medical device registration certificate for its fructosamine testing kit, which is expected to enhance its product line in the in vitro diagnostic sector [5] - Yihuilong has obtained registration for its anti-phosphatidylserine/prothrombin IgM and IgG antibody testing kits, which will expand its automated chemiluminescence product line [6] - Kangzheng Pharmaceutical's oral JAK1 inhibitor, Povorcitinib, has been included in the "Breakthrough Therapy" list for treating non-segmental vitiligo in adults [7] Capital Market Activities - Fosun Pharma plans to invest a total of 1.412 billion yuan in Green Valley Pharmaceutical, acquiring a 53% stake through its subsidiary [9] - Paig Bio-Medical has announced a further extension of the lock-up period for cornerstone investors until April 30, 2026, and is raising approximately 296 million HKD for various strategic initiatives [10][11] Industry Developments - Nanjing has established a medical health merger and acquisition equity investment fund with a total investment of 800 million yuan, focusing on equity investment and asset management [13] - Zhenghai Bio has signed a 12 million yuan technical development contract with the Chinese Academy of Agricultural Sciences for the research and development of recombinant type III collagen products [14] - MicroPort Robotics has established a new medical technology company with a registered capital of 15 million yuan, focusing on the development and manufacturing of service robots [15] Public Opinion Alerts - Tongrentang has responded to allegations of false labeling regarding its Antarctic krill oil product, initiating legal action against the involved parties to protect consumer rights [17]

Policy Developments - The National Healthcare Security Administration (NHSA) has issued a three-year action plan to enhance the efficiency of medical insurance fund settlement, aiming to complete annual settlements by March 31 each year starting in 2028, with settlement funds accounting for about 3% of the annual medical insurance fund allocation [2] - This plan represents a systemic reform of the medical insurance system, addressing issues such as slow reimbursements for insured individuals and funding for medical institutions in the short term, while promoting scientific and refined management of medical insurance funds in the medium term [2] Medical Device Registration - The Deputy Director of the National Medical Products Administration, Lei Ping, attended a regional meeting on medical device registration management and conducted field research in Guangdong and Yunnan, emphasizing the need to align with the health demands of the people and plan for high-quality development in the medical device sector [3] Company Announcements - Jiukang Bio has received a medical device registration certificate for its fructosamine testing kit, which is expected to enhance its competitiveness in the in vitro diagnostic market, although future sales remain uncertain [5] - Yihuilong has obtained registration for its anti-phosphatidylserine/prothrombin IgM and IgG antibody testing kits, which will expand its product line in the autoimmune disease testing sector, with sales dependent on market conditions [6] - Kangzheng Pharmaceutical announced that its oral JAK1 inhibitor, Povorcitinib, has been included in the "Breakthrough Therapy" list for treating non-segmental vitiligo in adults [7] Capital Market Activities - Fosun Pharma plans to invest a total of 1.412 billion yuan in Green Valley Pharmaceutical, acquiring a 53% stake through its subsidiary [9] - Paig Bio Pharma-B has announced a further extension of the lock-up period for cornerstone investors until April 30, 2026, and is raising approximately 296 million HKD for various strategic initiatives [10] Industry Developments - A new medical health equity investment fund has been established in Nanjing with a total investment of 800 million yuan, focusing on private equity investments and asset management [12] - Zhenghai Bio has signed a 12 million yuan technology development contract with the Chinese Academy of Agricultural Sciences for the research and development of recombinant type III collagen products [13] - Beijing Weisi Weixiang Medical Technology Co., Ltd. has been established with a registered capital of 15 million yuan, focusing on the development and manufacturing of service robots [14] - Tongrentang Health has taken action against a product falsely labeled as produced by its subsidiary, initiating legal proceedings to protect consumer rights [15]

抗磷脂综合征（antiphospholipid syndrome，APS）是以反复血栓形成、病态妊娠以及血清中抗磷脂抗体 （antiphospholipid antibody，aPL）持续阳性为特征的一种自身免疫性疾病。APS 的现行实验室标准包 括狼疮抗凝物（LA）、抗心磷脂（aCL）和抗β2-糖蛋白 I（aβ2-GPI）抗体的检测实验。有部分患者临 床最终诊断为APS，但LA，aCL 和 aβ2-GPI 检测为阴性，此类病例目前归为血清学阴性的抗磷脂综合 征（seronegative APS，SNAPS）。多项研究表明，抗磷脂酰丝氨酸/凝血酶原复合物抗体（anti- phosphatidylserine/prothrombin complex antibodies，aPS/PT）是SNAPS诊断最有价值的新磷脂抗体，与 LA 具有良好的一致性，可作为LA 的替代实验，是最有价值纳入 APS 诊断抗磷脂抗体谱的新型 aPL。 有文献研究表明，在体内凝血因子Va和Xa 存在的条件下，aPS/PT 能够促进凝血酶的生成及凝血酶原与 磷脂的结合，aPS/PT促进凝血酶生成的作用可能是 aPS/PT 与 APS 中 ...

智通财经APP讯，亚辉龙(688575.SH)发布公告，公司全资子公司湖南亚辉龙生物科技有限公司于近日 收到了由湖南省药品监督管理局签发的医疗器械注册证，产品名称：抗磷脂酰丝氨酸/凝血酶原IgM抗体 测定试剂盒(化学发光法)、抗磷脂酰丝氨酸/凝血酶原IgG抗体测定试剂盒(化学发光法)。 ...

截至目前，公司已先后取得178项化学发光试剂国内《医疗器械注册证》（共255个发光试剂国内注册 证）。本次《医疗器械注册证》的取得，有利于进一步丰富公司的全自动化学发光产品线，完善亚辉龙 的自身免疫性疾病领域检测套餐。 格隆汇12月15日丨亚辉龙(688575.SH)公布，公司全资子公司湖南亚辉龙生物科技有限公司于近日收到 了由湖南省药品监督管理局签发的医疗器械注册证。 产品名称：抗磷脂酰丝氨酸/凝血酶原 IgM 抗体测定试剂盒（化学发光法），注册编号：湘械注准 20252400986，产品名称：抗磷脂酰丝氨酸/凝血酶原 IgG 抗体测定试剂盒（化学发光法），注册编号： 湘械注准20252400987。 抗磷脂综合征（antiphospholipid syndrome，APS）是以反复血栓形成、病态妊娠以及血清中抗磷脂抗体 （antiphospholipid antibody，aPL）持续阳性为特征的一种自身免疫性疾病。APS 的现行实验室标准包 括狼疮抗凝物（LA）、抗心磷脂（aCL）和抗β2-糖蛋白 I（aβ2-GPI）抗体的检测实验。有部分患者临 床最终诊断为APS，但LA，aCL 和 aβ2-GPI ...

抗磷脂综合征（antiphospholipid syndrome，APS）是以反复血栓形成、病态妊娠 以及血清中抗磷脂抗体（antiphospholipid antibody，aPL）持续阳性为特征的一种自 身免疫性疾病。APS 的现行实验室标准包括狼疮抗凝物（LA）、抗心磷脂（aCL）和抗 β2-糖蛋白 I（aβ2-GPI）抗体的检测实验。有部分患者临床最终诊断为 APS，但 LA， aCL 和 aβ2-GPI 检测为阴性，此类病例目前归为血清学阴性的抗磷脂综合征 （seronegative APS，SNAPS）。多项研究表明，抗磷脂酰丝氨酸/凝血酶原复合物抗体 （anti-phosphatidylserine/prothrombin complex antibodies，aPS/PT）是 SNAPS 诊断最有价值的新磷脂抗体，与 LA 具有良好的一致性，可作为 LA 的替代实验，是最有 深圳市亚辉龙生物科技股份有限公司 关于自愿披露全资子公司取得医疗器械注册证的公告 证券代码：688575 证券简称：亚辉龙 公告编号：2025-072 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 ...

Core Viewpoint - The announcement indicates that the wholly-owned subsidiary of the company, Hunan Yahui Long Biotechnology Co., Ltd., has received medical device registration certificates for two antibody testing kits, enhancing its product line in the field of autoimmune disease detection [1] Group 1 - The registered products are the anti-phosphatidylserine/prothrombin IgM antibody test kit and the anti-phosphatidylserine/prothrombin IgG antibody test kit, both utilizing chemiluminescence methods [1] - The registration numbers for the products are 湘械注准20252400986 and 湘械注准20252400987, with a validity period until December 11, 2030 [1] - The acquisition of these registration certificates will help to further enrich the company's fully automated chemiluminescence product line [1]